PF-03814735, with the CAS number 942487-16-3, is a chemical compound that has been studied primarily for its potential therapeutic applications. It is classified as a small molecule and is known to act as a selective inhibitor of certain protein kinases, which play crucial roles in various cellular processes, including cell growth and division. The compound exhibits a specific affinity for its target, making it a candidate for research in the treatment of diseases such as cancer. Its molecular structure includes functional groups that contribute to its biological activity and solubility. In terms of physical properties, PF-03814735 is typically characterized by its stability under standard laboratory conditions, although specific solubility and melting point data may vary. As with many investigational compounds, further studies are necessary to fully understand its pharmacokinetics, efficacy, and safety profile in clinical settings. Overall, PF-03814735 represents a significant area of interest in medicinal chemistry and drug development.

The Aurora kinases are a family of serine/threonine kinases that are key regulators of mitosis and cytokinesis. PF-
03814735 is a reversible inhibitor of both Aurora A and B kinases with IC
50
values of 0.8 and 5 nM, respectively, in
in vitro
activity assays. PF-
03814735 also inhibits the kinases FLT1, FAK, TrkA, Met, and FGFR1 with IC
50
values of 10, 22, 30, 100, and 100 nM, respectively. PF-
03814735 inhibits cell proliferation of HCT116, HL-
60, A549, and H125 tumor cell lines with IC
50
values ranging from 42-
150 nM and shows
in vivo
efficacy in an HCT116 tumor xenograft mouse model. PF-
03814735 has been shown to be particularly sensitive towards inhibiting the growth of small cell lung cancer cell lines and other tumors driven by the Myc family genes.

PF-03814735

942487-16-3: PF-03814735, with the CAS number 942487-16-3, is a chemical compound that has been studied primarily for its potential therapeutic applications. It is classified as a small molecule and is known to act as a selective inhibitor of certain protein kinases, which play crucial roles in various cellular processes, including cell growth and division. The compound exhibits a specific affinity for its target, making it a candidate for research in the treatment of diseases such as cancer. Its molecular structure includes functional groups that contribute to its biological activity and solubility. In terms of physical properties, PF-03814735 is typically characterized by its stability under standard laboratory conditions, although specific solubility and melting point data may vary. As with many investigational compounds, further studies are necessary to fully understand its pharmacokinetics, efficacy, and safety profile in clinical settings. Overall, PF-03814735 represents a significant area of interest in medicinal chemistry and drug development.

PF-03814735 is a novel, potent and reversible inhibitor of Aurora A/B with IC50of 0.8 nM/5 nM, is less potent to Flt3, FAK, TrkA, and minimally active to Met and FGFR1. Phase 1.

CAS 942487-16-3

PF-03814735

PF-03814735

Ref: IN-DA00GU5D

PF-03814735

Ref: TM-T6936

PF 03814735

Ref: 3D-FP104134